Ezetimibe: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 10: | Line 10: | ||
==Medical uses== | ==Medical uses== | ||
Ezetimibe has been studied in several [[randomized controlled trial]]s.<ref name="pmid18376000">{{cite journal |author=Kastelein JJ, Akdim F, Stroes ES, ''et al'' |title=Simvastatin with or without ezetimibe in familial hypercholesterolemia |journal=N. Engl. J. Med. |volume=358 |issue=14 |pages=1431–43 |year=2008 |month=April |pmid=18376000 |doi=10.1056/NEJMoa0800742 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18376000&promo=ONFLNS19 |issn=}}</ref><ref name="pmid18765433">{{cite journal |author=Rossebø AB, Pedersen TR, Boman K, ''et al'' |title=Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis |journal=N. Engl. J. Med. |volume= |issue= |pages= |year=2008 |month=September |pmid=18765433 |doi=10.1056/NEJMoa0804602 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18765433&promo=ONFLNS19 |issn=}}</ref> The ENHANCE trial found no benefit in patients with familial [[hypercholesterolemia]].<ref name="pmid18376000"/> The trial was published in 2008 although Schering-Plough completed the trial in April 2006. The SEAS trial found no benefit on [[aortic stenosis]]. Pending studies of ezetimibe are | Ezetimibe has been studied in several [[randomized controlled trial]]s.<ref name="pmid18376000">{{cite journal |author=Kastelein JJ, Akdim F, Stroes ES, ''et al'' |title=Simvastatin with or without ezetimibe in familial hypercholesterolemia |journal=N. Engl. J. Med. |volume=358 |issue=14 |pages=1431–43 |year=2008 |month=April |pmid=18376000 |doi=10.1056/NEJMoa0800742 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18376000&promo=ONFLNS19 |issn=}}</ref><ref name="pmid18765433">{{cite journal |author=Rossebø AB, Pedersen TR, Boman K, ''et al'' |title=Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis |journal=N. Engl. J. Med. |volume= |issue= |pages= |year=2008 |month=September |pmid=18765433 |doi=10.1056/NEJMoa0804602 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18765433&promo=ONFLNS19 |issn=}}</ref> The ENHANCE trial found no benefit in patients with familial [[hypercholesterolemia]].<ref name="pmid18376000"/> The trial was published in 2008 although Schering-Plough completed the trial in April 2006. The SEAS trial found no benefit on [[aortic stenosis]]. Pending studies of ezetimibe are IMPROVE-IT (acute coronary syndrome) and SHARP (Study of Heart and Renal Protection.<ref name="pmid18314425">{{cite journal |author=Mitka M |title=Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct |journal=JAMA |volume=299 |issue=8 |pages=885–7 |year=2008 |month=February |pmid=18314425 |doi=10.1001/jama.299.8.885 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=18314425 |issn=}}</ref> | ||
==References== | ==References== | ||
Revision as of 12:12, 12 September 2008
Ezetimibe, sold under the brand names Ezedoc®, Zetia® and Ezetrol®, is an anti-hyperlipidemic medication used to lower cholesterol levels. It appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes. This mechanism differs from those of other classes of cholesterol-reducing compounds (HMG-CoA reductase inhibitors, bile acid sequestrants, fibric acid derivatives, and plant stanols). Ezetimibe does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion but instead localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of HMG-CoA reductase inhibitors.
Its chemical IUPAC name is (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl) azetidin-2-one and its chemical formula is C24H21F2NO3.
Drug interactions
Cholestyramine decreases the levels of ezetimibe while cyclosporine increases the effect and toxicity of ezetimibe. Ezetimibe can be taken without regard to food.
Medical uses
Ezetimibe has been studied in several randomized controlled trials.[1][2] The ENHANCE trial found no benefit in patients with familial hypercholesterolemia.[1] The trial was published in 2008 although Schering-Plough completed the trial in April 2006. The SEAS trial found no benefit on aortic stenosis. Pending studies of ezetimibe are IMPROVE-IT (acute coronary syndrome) and SHARP (Study of Heart and Renal Protection.[3]
References
- ↑ 1.0 1.1 Kastelein JJ, Akdim F, Stroes ES, et al (April 2008). "Simvastatin with or without ezetimibe in familial hypercholesterolemia". N. Engl. J. Med. 358 (14): 1431–43. DOI:10.1056/NEJMoa0800742. PMID 18376000. Research Blogging.
- ↑ Rossebø AB, Pedersen TR, Boman K, et al (September 2008). "Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis". N. Engl. J. Med.. DOI:10.1056/NEJMoa0804602. PMID 18765433. Research Blogging.
- ↑ Mitka M (February 2008). "Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct". JAMA 299 (8): 885–7. DOI:10.1001/jama.299.8.885. PMID 18314425. Research Blogging.
External Links
- Ezetimibe - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Template:MedMaster
- Template:DrugBank